본문 바로가기

logo

메뉴

  • COMPANY
    • About the Company
    • CEO’s Message
    • History
    • R&D Team
    • Direction
  • R&D
    • Pipeline
    • PINOT-ADC™
    • NTX-301
    • NTX-101
    • Business Performance
  • IR
    • Public Notice
  • PR
    • Notification
    • Press Release
    • Media Coverage
  • HOME
  • CONTACT
  • ENG
  • KOR
  • Leading
    Global Biotech,
    Pinotbio
  • COMPANY
    • About the Company
    • CEO’s Message
    • History
    • R&D Team
    • Direction
  • R&D
    • Pipeline
    • PINOT-ADC™
    • NTX-301
    • NTX-101
    • Business Performance
  • IR
    • Public Notice
  • PR
    • Notification
    • Press Release
    • Media Coverage
Pinobio Global Leading Biotech for Novel Anticancer Treatment
Pinobio Today's Curiosity will be Tomorrow's Cure
Pinobio A Revolutionary Approach to Cancer Therapy
R&D
  • PINOT-ADC™

    Next-generation ADC anticancer drug platform technology that overcomes the limitations of existing ADC drugs

  • NTX-301

    Best-in-class DNMT1 inhibitor targeted anticancer therapy in nucleoside-based drugs

  • NTX-101

    First-in-class eye drops that lower intraocular pressure and protect the optic nerve

IR&PR What's New
PR
Notification
IR/PR page is available in Korean.

2022.01.27
Media ADC Platform PINOT-ADC™ and PBX-001 Mechanism of Action
Address. 8F, 156, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
  • Fax. 031-8064-1303
  • E-mail ir@pinotbio.com

(C) 2021. PINOTBIO. All right reserved.